Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study is trying to figure out how much ORIC-533 is safe and effective for patients with multiple myeloma who have tried all other treatments. They want to see how the medicine works in the body and if it can help with the disease.
This study is trying to figure out how much ORIC-533 is safe and effective for patients with multiple myeloma who have tried all other treatments. They want to see how the medicine works in the body and if it can help with the disease.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antimyeloma activity of ORIC-533 in patients with multiple myeloma who have exhausted available treatment options
The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antimyeloma activity of ORIC-533 in patients with multiple myeloma who have exhausted available treatment options
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: